TY - JOUR AU - Mayer, R. J. AU - Cutsem, E. AU - Falcone, A. PY - 2015 DA - 2015// TI - Randomized trial of TAS-102 for refractory metastatic colorectal cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414325 DO - 10.1056/NEJMoa1414325 ID - Mayer2015 ER - TY - JOUR AU - Yamashita, F. AU - Komoto, I. AU - Oka, H. PY - 2015 DA - 2015// TI - Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2805-9 DO - 10.1007/s00280-015-2805-9 ID - Yamashita2015 ER - TY - JOUR AU - Tanaka, N. AU - Sakamoto, K. AU - Okabe, H. PY - 2014 DA - 2014// TI - Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models JO - Oncol Rep VL - 32 ID - Tanaka2014 ER - TY - STD TI - ClinicalTrials.gov. Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer. 2016; https://clinicaltrials.gov/ct2/show/NCT02286492. Accessed 15 June 2016. UR - https://clinicaltrials.gov/ct2/show/NCT02286492 ID - ref4 ER - TY - STD TI - Kotani D, Shitara K, Kawazoe A, et al. Safety and efficacy of trifluridine/tipiracil monotherapy in clinical practice for patients with metastatic colorectal cancer: experience at a single Institution. Clin Colorectal Cancer. 2015 [Epub ahead of print] ID - ref5 ER - TY - JOUR AU - Yoshino, T. AU - Mizunuma, N. AU - Yamazaki, K. PY - 2012 DA - 2012// TI - TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial JO - Lancet Oncol VL - 13 UR - https://doi.org/10.1016/S1470-2045(12)70345-5 DO - 10.1016/S1470-2045(12)70345-5 ID - Yoshino2012 ER - TY - JOUR AU - Doi, T. AU - Ohtsu, A. AU - Yoshino, T. PY - 2012 DA - 2012// TI - Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours JO - Br J Cancer VL - 107 UR - https://doi.org/10.1038/bjc.2012.274 DO - 10.1038/bjc.2012.274 ID - Doi2012 ER - TY - JOUR AU - Hong, D. S. AU - Abbruzzese, J. L. AU - Bogaard, K. PY - 2006 DA - 2006// TI - Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors JO - Cancer VL - 107 UR - https://doi.org/10.1002/cncr.22125 DO - 10.1002/cncr.22125 ID - Hong2006 ER - TY - JOUR AU - Bendell, J. C. AU - Rosen, L. S. AU - Mayer, R. J. PY - 2015 DA - 2015// TI - Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer JO - Cancer Chemother Pharmacol VL - 76 UR - https://doi.org/10.1007/s00280-015-2850-4 DO - 10.1007/s00280-015-2850-4 ID - Bendell2015 ER - TY - JOUR AU - Overman, M. J. AU - Varadhachary, G. AU - Kopetz, S. PY - 2008 DA - 2008// TI - Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors JO - Invest New Drugs VL - 26 UR - https://doi.org/10.1007/s10637-008-9142-3 DO - 10.1007/s10637-008-9142-3 ID - Overman2008 ER - TY - JOUR AU - Doi, T. AU - Yoshino, T. AU - Fuse, N. PY - 2015 DA - 2015// TI - Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer JO - Invest New Drugs VL - 33 UR - https://doi.org/10.1007/s10637-015-0271-1 DO - 10.1007/s10637-015-0271-1 ID - Doi2015 ER - TY - JOUR AU - Tewari, K. S. AU - Java, J. J. AU - Gatcliffe, T. A. AU - Bookman, M. A. AU - Monk, B. J. PY - 2014 DA - 2014// TI - Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group JO - Gynecol Oncol VL - 133 UR - https://doi.org/10.1016/j.ygyno.2014.03.013 DO - 10.1016/j.ygyno.2014.03.013 ID - Tewari2014 ER - TY - JOUR AU - Liu, R. AU - Huang, M. AU - Zhao, X. PY - 2015 DA - 2015// TI - Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen JO - Oncotarget VL - 6 ID - Liu2015 ER -